Abstract:Background: Poor graft function (PGF) or prolonged isolated thrombocytopenia (PT), which are characterized by pancytopenia or thrombocytopenia, have become serious complications after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Our previous single-arm trial suggest that N-acetyl-L-cysteine (NAC) prophylaxis reduced PGF or PT after allo-HSCT. Aims: Investigate the efficacy and tolerability of NAC prophylaxis to reduce PGF or PT after allo-HSCT. Methods: A phase 3, open-label randomized trial was performed. Based on the percentage of CD34+VEGFR2(CD309)+ endothelial cells (ECs) in bone marrow (BM) detected by flow cytometry at 14d before conditioning, patients aged 15 to 60 years with acute leukemia undergoing haploidentical HSCT were categorized as low-risk(EC≥0.1%) or high-risk(EC<0.1%); patients at high risk were randomly assigned(2:1) to receive NAC prophylaxis or nonprophylaxis. The primary endpoint was PGF and PT incidence at +60d post-HSCT. Secondary endpoints included cumulative incidences of leukemia relapse(CIR), GvHD, nonrelapse mortality (NRM), leukemia-free survival (LFS), overall survival (OS), and adverse events. This clinical trial was registered at www.clinicaltrials.gov as # NCT03967665. Results: Between April 18, 2019, and June 24, 2021, 120 patients with BM EC <0.1% were randomly assigned for NAC (Group A, N=80) or nonprophylaxis (Group B, N=40), and 105 patients with EC≥0.1% (Group C) were also analyzed. The +60d incidence of PGF and PT was 7.5% (95% CI, 1.7% to 13.3%) and 22.5% (95% CI, 9.1% to 35.9%) in Group A and Group B (hazards ratio, 0.317; 95% CI, 0.113 to 0.890; P = .021) and 11.4% (95% CI, 5.2% to 17.6%) in Group C (hazards ratio, 0.643; 95% CI, 0.242 to 1.715; P = .373) (Figure A). Consistently, NAC prophylaxis gradually improved BM ECs and CD34+ cells in Group A, whereas reduced their ROS levels post-HSCT. With a median follow-up of 347 days (range, 60-844days) post-HSCT, the 1-year probabilities relapse, NRM, OS (Figure B), and LFS (Figure C) were similar among the three groups. Within 60days post-HSCT, the most common grade 3 to 5 adverse events for the NAC and control groups were infections (19/80 [24%] vs. 10/40 [25%]) and gastrointestinal adverse events (16/80 [20%] vs. 7/40 [18%]). There were no treatment-related deaths. Image:Summary/Conclusion: N-acetyl-L-cysteine prophylaxis can prevent the occurrence of poor hematopoietic function and is well tolerated in haploidentical HSCT. It may offer a potential pathogenesis-oriented therapeutic approach for patients with poor hematopoietic function.

Mechanisms of Antioxidant Induction with High-Dose N-Acetylcysteine in Childhood Cerebral Adrenoleukodystrophy

Prophylactic oral NAC reduced poor hematopoietic reconstitution by improving endothelial cells after haploidentical transplantation

N‐acetyl‐L‐cysteine Improves Bone Marrow Endothelial Progenitor Cells in Prolonged Isolated Thrombocytopenia Patients Post Allogeneic Hematopoietic Stem Cell Transplantation

Prophylactic NAC promoted hematopoietic reconstitution by improving endothelial cells after haploidentical HSCT: a phase 3, open-label randomized trial

P1417: PROPHYLACTIC NAC PROMOTED HEMATOPOIETIC RECONSTITUTION BY IMPROVING ENDOTHELIAL CELLS AFTER HSCT: A PHASE 3, OPEN-LABEL RANDOMIZED TRIAL

Oxidative Imbalance, Nitrative Stress, and Inflammation in C6 Glial Cells Exposed to Hexacosanoic Acid: Protective Effect of N-acetyl-l-cysteine, Trolox, and Rosuvastatin

Antioxidant Therapy Significantly Attenuates Hepatotoxicity following Low Dose Exposure to Microcystin-LR in a Murine Model of Diet-Induced Non-Alcoholic Fatty Liver Disease

The Multifaceted Therapeutic Role of N-Acetylcysteine (NAC) in Disorders Characterized by Oxidative Stress

Effect of N-acetyl cysteine in children with metabolic dysfunction-associated steatotic liver disease-A pilot study

N-Acetylcysteine Alters Disease Progression and Increases Janus Kinase Mutation Frequency in a Mouse Model of Precursor B-Cell Acute Lymphoblastic Leukemia

Existing and potential therapeutic uses for N-acetylcysteine: The need for conversion to intracellular glutathione for antioxidant benefits

Bone marrow mononuclear cells boosts anti-cytogentical aberration effect of N-acetylcysteine and α-lipoic acid in rat's liver and bone marrow: implication of oxidative and inflammatory pathways

Antioxidant Response in Human X-Linked Adrenoleukodystrophy Fibroblasts

Oral N-acetylcysteine ameliorates liver fibrosis and enhances regenerative responses in Mdr2 knockout mice

N-Acetyl Cysteine Ameliorates High-Fat Diet-Induced Nonalcoholic Fatty Liver Disease and Intracellular Triglyceride Accumulation by Preserving Mitochondrial Function

N-acetylcysteine exposure is associated with improved survival in anti-nuclear antibody seropositive patients with usual interstitial pneumonia

Redox status, inflammation, necroptosis and inflammasome as indispensable contributors to high fat diet (HFD)-induced neurodegeneration; Effect of N-acetylcysteine (NAC)

N-acetyl-L-cysteine improves mesenchymal stem cell function in prolonged isolated thrombocytopenia post-allotransplant.

N-acetylcysteine attenuates atherosclerosis progression in aging LDL receptor deficient mice with preserved M2 macrophages and increased CD146

A randomized placebo-controlled pilot study of N-acetylcysteine in youth with autism spectrum disorder

N‐acetylcysteine Alleviated Paraquat‐induced Mitochondrial Fragmentation and Autophagy in Primary Murine Neural Progenitor Cells